On page 65, in column 1 of the “Patients and methods” section, the wrong study number was published. The first sentence under the heading “Study design and treatments” should read:

This was a randomized, double-blind, placebo-controlled, parallel-group, phase III trial (Study 14CL308) designed to evaluate the efficacy and safety of 6 and 12 mg alvimopan for the management of POI in patients undergoing BR or TAH.